NASDAQ:IRWD Ironwood Pharmaceuticals Q1 2025 Earnings Report $3.24 -0.04 (-1.22%) Closing price 04:00 PM EasternExtended Trading$3.21 -0.03 (-1.02%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ironwood Pharmaceuticals EPS ResultsActual EPS-$0.14Consensus EPS -$0.05Beat/MissMissed by -$0.09One Year Ago EPSN/AIronwood Pharmaceuticals Revenue ResultsActual Revenue$41.14 millionExpected Revenue$67.02 millionBeat/MissMissed by -$25.88 millionYoY Revenue GrowthN/AIronwood Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/7/2025TimeBefore Market OpensConference Call DateWednesday, May 7, 2025Conference Call Time7:00AM ETUpcoming EarningsIronwood Pharmaceuticals' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Ironwood Pharmaceuticals Earnings HeadlinesIs Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess?June 2 at 10:11 AM | insidermonkey.comIronwood Pharmaceuticals Signals Blockbuster Momentum in 2026June 1 at 8:31 PM | tipranks.comYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.June 3 at 1:00 AM | Profits Run (Ad)Equities Analysts Offer Predictions for IRWD FY2026 EarningsJune 1 at 1:20 AM | americanbankingnews.comIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2026 | businesswire.comIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Pass Above 200 Day Moving Average - Here's WhyMay 28, 2026 | americanbankingnews.comSee More Ironwood Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ironwood Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ironwood Pharmaceuticals and other key companies, straight to your email. Email Address About Ironwood PharmaceuticalsIronwood Pharmaceuticals (NASDAQ:IRWD) is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S. markets under the brand name CONSTELLA. In addition to its marketed therapy, Ironwood maintains a diversified pipeline of clinical and preclinical programs targeting GI motility, inflammation and neurological conditions. Lead pipeline candidates include novel small molecules designed to modulate gut motility and secretions, as well as agents aimed at central nervous system targets to address pain and neurodegenerative disorders. The company leverages in-house research capabilities alongside external partnerships to advance its portfolio. Founded in 1998 as Microbia Biosciences, the business rebranded as Ironwood Pharmaceuticals in 2010 concurrent with its initial public offering. Headquartered in Cambridge, Massachusetts, Ironwood conducts research and development activities in the U.S. and collaborates with global pharmaceutical partners to extend its reach into European, Canadian and other international markets. Ironwood is led by President and Chief Executive Officer Peter Hecht, who brings extensive experience in both commercial operations and strategic development within the biopharmaceutical industry. Under his leadership, the company continues to pursue innovative therapies aimed at addressing unmet needs in GI health and related therapeutic areas.View Ironwood Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palo Alto Networks Accelerates Growth 31% on AI DemandUrban Outfitters Stock Stalls Despite Another Strong QuarterMarvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNowHIVE Earnings Highlight AI Ambitions Beyond Bitcoin MiningMongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today"Dollar General Signals Reversal With 60% Rebound PotentialKohl's Stock Soars After Better-Than-Feared Quarter Upcoming Earnings Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
